New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Negotiating and Structuring Strategic Alliances
by David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Advertisement
Articles in this issue
over 24 years ago
Finding Funding in Biotechnology: Keeping the Companies Aliveover 24 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 24 years ago
Unlocking the Value of R&D: Managing the Risksover 24 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 24 years ago
Inside Washington: Safety, Risk, and Biotechnology Regulationover 24 years ago
Criminal Penalties for Theft of Biological MaterialAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement